H.C. Wainwright initiated coverage on Virax Biolabs Group Ltd. with a new price target

3/31/25 8:25:16 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VRAX

Date	Price Target	Rating	Analyst
3/31/2025	$3.00	Buy	H.C. Wainwright